Accepted for Publication: December 4, 2011.
Author Contributions:Study concept and design: Alam, Gomes, Mamdani, Juurlink, and Bell. Acquisition of data: Alam, Zheng, and Bell. Analysis and interpretation of data: Alam, Gomes, Mamdani, Juurlink, and Bell. Drafting of the manuscript: Alam, Zheng, and Bell. Critical revision of the manuscript for important intellectual content: Alam, Gomes, Mamdani, Juurlink, and Bell. Statistical analysis: Alam, Zheng, Mamdani, Juurlink, and Bell. Obtained funding: Alam, Juurlink, and Bell. Administrative, technical, and material support: Alam and Mamdani. Study supervision: Juurlink and Bell.
Financial Disclosure: Dr Mamdani reported having served on advisory boards for the following companies: Hoffman La Roche, GlaxoSmithKline, Pfizer, Novartis, Eli Lilly and Company, Novo Nordisk, Astra Zeneca, and Bristol-Myers Squibb.
Funding/Support: This study was supported by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. Dr Bell is supported by a Canadian Institutes of Health Research and Canadian Patient Safety Institute chair in Patient Safety and Continuity of Care. The Ontario Drug Policy Research Network/Ministry of Health and Long-Term Care fully funded this project.
Role of Sponsors: These funding agencies had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; or preparation, review, or approval of the manuscript.
Disclaimer: The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by the Institute for Clinical Evaluative Sciences or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred.